Abstract

Background/aimsFinancial compensation for research participation is a major focus of ethical concern regarding human subject recruitment. Phase I trials are sometimes considered to be a lucrative source of income for healthy volunteers, encouraging some people to become “professional guinea pigs.” Yet, little is known about how much these clinical trials actually pay and how much healthy volunteers earn from them.MethodsAs part of a mixed-methods, longitudinal study of healthy volunteers, we required participants to complete clinical trial diaries, or surveys that captured detailed information about screening and enrollment in Phase I trials. Over a 3-year period, participants provided information online or via telephone about each clinical trial for which they screened (e.g. the clinic name, the study’s therapeutic area, the length of the trial, the number of nights spent in the clinic, and the study compensation), and whether they qualified for trial inclusion. Clinical trial diaries generated data about whether participants continued to screen for and enroll in clinical trials and how much money they earned from their participation.Results131 participants routinely completed clinical trial diaries or confirmed that they had not screened for any new clinical trials. Together, these participants screened for 1001 clinical trials at 73 research facilities during a 3-year period. Overall, the median clinical trial compensation was US$3070 (range = US$150–US$13,000). Participants seeking new healthy volunteer trials tended to screen for three studies per year, participate in one or two studies, and earn roughly US$4000 annually. Participants who were unemployed earned the most income from clinical trials compared to those with full-time or part-time jobs, and those individuals whom we label “occupational” participants because of their persistent pursuit of clinical trials earned more than people who screened occasionally. Notably, the median annual trial compensation was well below US$10,000 for all employment groups, and most occupational healthy volunteers also earned less than US$10,000 each year. The 10% of participants who earned the most had a median annual income of US$18,885 from clinical trials, and there was significant volatility in these individuals’ earnings from year to year.ConclusionDespite the perception that Phase I enrollment can generate significant earnings, it was exceedingly rare for anyone in this study to make more than US$20,000 in a single year, and unusual to earn even between US$10,000 and US$20,000. From an ethics perspective, individual trials might appear to unduly induce enrollment by offering significant sums of money, but given our findings, the larger problem for low-income participants may be the unrealistic perception that clinical trials alone could be a way of earning a living.

Highlights

  • Background/aims: Financial compensation for research participation is a major focus of ethical concern regarding human subject recruitment

  • By taking the scholarly and popular literature at face value, Phase I trials are a lucrative source of income, such as when it is suggested that healthy volunteers can earn over US$30,000 annually from clinical trials.[21,22,23]

  • A research participation website even suggests that healthy volunteers can ‘‘theoretically’’ enroll in six to seven trials and earn an average of US$18,000 to US$28,000 annually by ‘‘do[ing] studies for a living.’’24 Examining Phase I participation is crucial to providing insights into what can be expected as typical trial earnings, as well as the upper limits of what healthy volunteers might make when they pursue clinical trials persistently

Read more

Summary

Introduction

Background/aims: Financial compensation for research participation is a major focus of ethical concern regarding human subject recruitment. Despite significant attention to the ethics of Phase I trial compensation and concerns about so-called professional participation, little is known about how much these trials pay and how much healthy volunteers can expect to earn, either through occasional enrollment or more concerted effort to earn a living. This empirically grounded snapshot of clinical trial compensation can subsequently shed light on which ethical concerns are the most salient in the context of Phase I trials

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.